JEFFREY GRAY: Open Payments
NPI 1033478748 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$899 in 37 payments from 9 companies in 2025. Trend: 2023 $839 · 2024 $1,244 · 2025 $899
Food & beverage: $899
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 10 | $271 |
| Neurocrine BioSciences, Inc. | 8 | $165 |
| Janssen Pharmaceuticals, Inc | 5 | $160 |
| Teva Pharmaceuticals USA, Inc. | 7 | $146 |
| E.R. Squibb & Sons, L.L.C. | 2 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| Alkermes, Inc. | 1 | $27 |
| Lundbeck LLC | 1 | $25 |
| ABBVIE INC. | 1 | $15 |
Products named: CAPLYTA, INGREZZA, INVEGA SUSTENNA, UZEDY, AUSTEDO XR, COBENFY, ABILIFY ASIMTUFII, ARISTADA.
Industry payments across CA — which companies pay providers there.
